非骨关节炎适应症的选择性全髋关节置换术与费用和资源使用增加相关:一项135194例索赔的医疗保险数据库研究
基于2019年Medicare数据,分析135194例选择性全髋关节置换术,比较六种手术适应症(骨关节炎、类风湿关节炎、股骨头坏死、髋关节发育不良、创伤后关节炎和转换关节置换术)的医院费用、住院时间、出院去向和ICU使用。与非骨关节炎适应症相比,股骨头坏死、髋关节发育不良、创伤后关节炎和转换关节置换术的费用呈阶梯式增加,主要由医疗和手术耗材及手术室资源驱动。
要点
- 股骨头坏死、髋关节发育不良、创伤后关节炎和转换关节置换术的费用较骨关节炎分别高5%、13%、22%和40%。
- 所有非骨关节炎适应症的住院时间延长和非家庭出院 odds 均增加。
- 创伤后关节炎和转换关节置换术资源使用增加最大,固定支付下可致经济损失。
核心结论
- 与骨关节炎全髋关节置换术相比,股骨头坏死、髋关节发育不良、创伤后关节炎和转换关节置换术与资源使用阶梯式增加独立相关,主要由医疗和手术耗材及手术室资源需求增加驱动。
研究设计与样本
- 使用2019年Medicare提供者分析和审查有限数据集,识别选择性初次全髋关节置换术,排除非按服务收费、非择期、数据缺失及六种适应症以外的病例,最终分析135194例。
- 医院费用通过CMS成本电荷比估算,采用多变量广义线性模型控制患者人口学、术前健康状况和医院特征。
主要发现
- 股骨头坏死全髋关节置换术费用是骨关节炎的1.050倍(95%CI 1.042-1.069;p<0.001),高5%。
- 髋关节发育不良费用是骨关节炎的1.132倍(95%CI 1.113-1.152;p<0.001),高13%。
- 创伤后关节炎费用是骨关节炎的1.220倍(95%CI 1.193-1.246;p<0.001),高22%。
- 转换关节置换术费用是骨关节炎的1.403倍(95%CI 1.386-1.419;p<0.001),高40%;类风湿关节炎与费用增加无关。
- 所有研究的骨科疾病与骨关节炎相比,住院时间延长和非家庭出院 odds 均增加;股骨头坏死、创伤后关节炎和转换关节置换术还与ICU使用增加相关。
关键数值与推荐
- 费用比较以骨关节炎为参照,股骨头坏死、髋关节发育不良、创伤后关节炎和转换关节置换术的费用依次递增,置信区间不重叠。
- 医疗或手术耗材和手术室收费是各手术适应症费用增加的主要驱动因素。
临床怎么用
- 高比例开展非骨关节炎适应症全髋关节置换术的医院应预算预期费用增加。
- 骨科医生应倡导改进MS-DRG编码,以合理补偿医院对这些手术的财务和临床风险。
局限性
- 证据等级为IV级,经济与决策分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Under Medicare's fee-for-service and bundled payment models, the basic unit of hospital payment for inpatient hospitalizations is determined by the Medicare Severity Diagnosis Related Group (MS-DRG) coding system. Primary total joint arthroplasties (hip and knee) are coded under MS-DRG code 469 for hospitalizations with a major complication or comorbidity and MS-DRG code 470 for those without a major complication or comorbidity. However, these codes do not account for the indication for surgery, which may influence the cost of care.Questions/purposes We sought to (1) quantify the differences in hospital costs associated with six of the most common diagnostic indications for THA (osteoarthritis, rheumatoid arthritis, avascular necrosis, hip dysplasia, posttraumatic arthritis, and conversion arthroplasty), (2) assess the primary drivers of cost variation using comparisons of hospital charge data for the diagnostic indications of interest, and (3) analyze the median length of stay, discharge destination, and intensive care unit use associated with these indications. METHODS: This study used the 2019 Medicare Provider Analysis and Review Limited Data Set. Patients undergoing primary elective THA were identified using MS-DRG codes and International Classification of Diseases, Tenth Revision, Procedure Coding System codes. Exclusion criteria included non-fee-for-service hospitalizations, nonelective procedures, patients with missing data, and THAs performed for indications other than the six indications of interest. A total of 713,535 primary THAs and TKAs were identified in the dataset. After exclusions were applied, a total of 135,194 elective THAs were available for analysis. Hospital costs were estimated using cost-to-charge ratios calculated by the Centers for Medicare and Medicaid Services. The primary benefit of using cost-to-charge ratios was that it allowed us to analyze a large national dataset and to mitigate the random cost variation resulting from unique hospitals' practices and patient populations. As an investigation into matters of health policy, we believe that assessing the surgical cost borne by the "average" hospital was most appropriate. To analyze estimated hospital costs, we performed a multivariable generalized linear model controlling for patient demographics (gender, age, and race), preoperative health status, and hospital characteristics (hospital setting [urban versus rural], geography, size, resident-to-bed ratio, and wage index). We assessed the principal drivers of cost variation by analyzing the median hospital charges arising from 30 different hospital revenue centers using descriptive statistics. Length of stay, intensive care use, and discharge to a nonhome location were analyzed using multivariable binomial logistic regression. RESULTS: The cost of THA for avascular necrosis was 1.050 times (95% confidence interval 1.042 to 1.069; p < 0.001), or 5% greater than, the cost of THA for osteoarthritis; the cost of hip dysplasia was 1.132 times (95% CI 1.113 to 1.152; p < 0.001), or 13% greater; the cost of posttraumatic arthritis was 1.220 times (95% CI 1.193 to 1.246; p < 0.001), or 22% greater; and the cost of conversion arthroplasty was 1.403 times (95% CI 1.386 to 1.419; p < 0.001), or 40% greater. Importantly, none of these CIs overlap, indicating a discernable hierarchy of cost associated with these diagnostic indications for surgery. Rheumatoid arthritis was not associated with an increase in cost. Medical or surgical supplies and operating room charges represented the greatest increase in charges for each of the surgical indications examined, suggesting that increased use of medical and surgical supplies and operating room resources were the primary drivers of increased cost. All of the orthopaedic conditions we investigated demonstrated increased odds that a patient would experience a prolonged length of stay and be discharged to a nonhome location compared with patients undergoing THA for osteoarthritis. Avascular necrosis, posttraumatic arthritis, and conversion arthroplasty were also associated with increased intensive care unit use. Posttraumatic arthritis and conversion arthroplasty demonstrated the largest increase in resource use among all the orthopaedic conditions analyzed. CONCLUSION: Compared with THA for osteoarthritis, THA for avascular necrosis, hip dysplasia, posttraumatic arthritis, and conversion arthroplasty is independently associated with stepwise increases in resource use. These cost increases are predominantly driven by greater requirements for medical and surgical supplies and operating room resources. Posttraumatic arthritis and conversion arthroplasty demonstrated substantially increased costs, which can result in financial losses in the setting of fixed prospective payments. These findings underscore the inability of MS-DRG coding to adequately reflect the wide range of surgical complexity and resource use of primary THAs. Hospitals performing a high volume of THAs for indications other than osteoarthritis should budget for an anticipated increase in costs, and orthopaedic surgeons should advocate for improved MS-DRG coding to appropriately reimburse hospitals for the financial and clinical risk of these surgeries. LEVEL OF EVIDENCE: Level IV, economic and decision analysis.
引用
- Blackburn CW, Du JY, Marcus RE, et al. Elective THA for Indications Other Than Osteoarthritis Is Associated With Increased Cost and Resource Use: A Medicare Database Study of 135,194 Claims. Clin Orthop Relat Res. 2023. PMID: 38011034. doi:10.1097/CORR.0000000000002922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。